YiCe Technology has recently concluded a Pre-A round financing of tens of millions of yuan, led by Wanyuandian Fund and joined by Oufang Angel and Guangzhou Bio Island Life Science Innovation and Entrepreneurship Investment Fund. This capital injection will primarily fuel the advancement of large pathological models and the commercialization of pharmaceutical R&D services. Since its inception in 2021, YiCe Technology has been dedicated to developing AI products and solutions in smart pathology and pharmaceutical R&D. The company has proudly introduced the "Lingmou" multimodal large pathological model, which spans multiple pathology domains and aids in the diagnosis of numerous tumor subtypes, achieving clinical-grade interpretation accuracy. Furthermore, YiCe Technology has constructed an "AI+IVD&CRO" industrial ecosystem and collaborated with several leading institutions to collectively propel the adoption of AI in pathology. Moving forward, YiCe Technology aims to strengthen ties with strategic partners and foster the dual-platform development of "Pharmaceutical R&D Pathology CRO + Clinical Diagnostic Pathology," with aspirations to become a leading enterprise in the global AI medical industry.